Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating
Nurix Therapeutics (NRIX) Receives a Buy From Wells Fargo
Morgan Stanley Reaffirms Their Hold Rating on Ionis Pharmaceuticals (IONS)
Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)
Nurix Therapeutics Analyst Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Recursion Pharmaceuticals Analyst Ratings
Schrodinger Analyst Ratings
Nephron Initiates CareDx at Hold Rating With $15 Price Target
Twist Bioscience Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Schrodinger Analyst Ratings
Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Ionis Pharmaceuticals Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings